Spica Therapeutics
PrivateLast Round
Grant
Aug 27, 2025
Total Funding Raised
$12.54M
Company Overview
Spica Therapeutics operates in Healthcare & Life Sciences and is based in Antwerp. Its latest recorded funding round was a Grant round in August 2025.
Spica Therapeutics is a biotechnology company that develops macrophage-subset targeted therapies using a proprietary functional fingerprinting platform to address oncology and fibroinflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Spica Therapeutics Comparables
Compare Spica Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Macomics | 87% | |
| DEM BioPharma | 79% | |
| Resolute Science | 79% |
For institutional investors. Book with your work email.
Spica Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 27, 2025 | ||||
| Seed | Jun 4, 2025 |
For institutional investors. Book with your work email.
Spica Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| VLAIO | Grant |
| Bioqube Ventures | Seed |
| PMV | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2026
Monthly visitors increased 47% MoM.
- Aug 27, 2025
$1.2M grant received
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 27, 2026
Spicatx appoints Jeff Abbey as Chief Executive Officer in Belgium in Oct '26, as the biotech company plans to expand its Macrophage Fingerprinting Platform beyond oncology to other chronic conditions.
For institutional investors. Book with your work email.
Spica Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Spica Therapeutics's valuation, stock price, and market status.
Is Spica Therapeutics a public or private company?
Spica Therapeutics is a private company.
What is the current stock price of Spica Therapeutics?
Spica Therapeutics is a private company, so its shares have no public market price. Caplight tracks Spica Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Spica Therapeutics worth (valuation)?
Valuation information for Spica Therapeutics is not publicly available.
Can I buy Spica Therapeutics stock?
Spica Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Spica Therapeutics's last funding round?
Spica Therapeutics's most recent funding round was Grant on August 27, 2025.
Who are the main investors in Spica Therapeutics?
Key investors in Spica Therapeutics include Bioqube Ventures, PMV.
Will Spica Therapeutics IPO soon?
No public IPO plans have been announced for Spica Therapeutics.
How can I track Spica Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Spica Therapeutics's shares on secondary markets.